In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

Novo Nordisk (NYSE:NVO) rose to its highest level in over two months Monday after a media report said hedge fund Parvus Asset ...

STARING at yet another pregnancy test, Erica Coronado was thrilled but terrified. The 36-year-old had given up hope of a baby ...

Novo Nordisk (NVO) shares hit their highest level in over two months following a Financial Times report that activist hedge ...

Aleniglipron’s tolerability could be a differentiator for Structure Therapeutics, but its efficacy lags competitors. Read why ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk, after the company lost its first mover ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

Metsera Inc.’s shares jumped after the obesity startup shared better-than-expected data on a weight-loss shot that would ...

Metsera has linked its amylin analog to 8.4% placebo-adjusted weight loss at Day 36, advancing its push to develop an ...